文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

喀麦隆未治疗HIV-1感染者INSTI耐药突变流行率

Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究在喀麦隆四家医院采集2015至2016年339例新诊断HIV-1感染者的干血斑样本,用Illumina测序分析整合酶区耐药突变。255条序列中,以1%为阈值,5.1%个体检出INSTI主要耐药突变,但仅1例频率≥15%;54.9%个体携带多态性辅助INSTI耐药突变。结论认为研究地点治疗前INSTI耐药率低,支持INSTI使用。

要点

  • 喀麦隆新诊断HIV-1感染者治疗前INSTI主要耐药突变率低(1%阈值下5.1%)。
  • 仅1例携带频率≥15%的INSTI耐药突变(E92G)。
  • 54.9%个体携带多态性辅助INSTI耐药突变,需进一步评估其影响。

核心结论

  • 研究地点治疗前HIV-1对INSTI耐药率低,支持在喀麦隆使用INSTI。
  • 需进一步研究多态性辅助INSTI耐药突变对含INSTI方案的影响。

研究设计与样本

  • 2015至2016年在喀麦隆四家医院采集339例新诊断HIV-1感染者的指尖干血斑样本。
  • 设计通用引物扩增HIV-1整合酶区氨基酸1至276,采用Illumina下一代测序,并以PASeq平台和Stanford HIV耐药数据库解读耐药突变。

主要发现

  • 扩增/测序成功率为75.2%,339例中获得255条序列。
  • 以1%为阈值,13例(5.1%)检出INSTI主要耐药突变。
  • 仅1例携带频率≥15%的INSTI耐药突变(E92G)。
  • 140/255例(54.9%)携带多态性辅助INSTI耐药突变,主要呈高频率。
  • 个体间HIV-1亚型多样性高。

临床怎么用

  • 研究地点治疗前INSTI耐药率低,支持将INSTI用于喀麦隆HIV-1感染者的初始治疗。
  • 对携带多态性辅助INSTI耐药突变者的临床影响尚需进一步研究评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In Cameroon, the integrase (IN) strand transfer inhibitor (INSTI) dolutegravir was recently introduced for the treatment of HIV-1 infection. Since pretreatment HIV-1 drug resistance can jeopardize the success of ART, and considering the high heterogeneity of circulating HIV-1 subtypes in Cameroon, we investigated the prevalence of pretreatment HIV-1 resistance to INSTIs. METHODS: Fingerprick dried blood spot samples were collected from 339 newly diagnosed HIV-1-infected individuals between 2015 and 2016 in four hospitals in Cameroon. Universal primers were designed to amplify the HIV-1 IN region from amino acid 1 to 276. Amplicons were sequenced with Illumina next-generation sequencing and analysed with the Polymorphism Analysis Sequencing (PASeq) platform, using the Stanford HIV Drug Resistance Database to interpret HIV-1 drug resistance mutations (DRMs). RESULTS: The amplification/sequencing success rate was 75.2% with 255/339 sequences obtained. Applying a cut-off of 1%, major DRMs to INSTIs were detected in 13 (5.1%) individuals, but only 1 individual harboured an INSTI DRM (E92G) at a nucleotide frequency ≥15%. However, 140/255 (54.9%) individuals harboured polymorphic accessory INSTI DRMs, mainly at high frequencies. In line with that observation, HIV-1 subtype diversity among individuals was high. CONCLUSIONS: Pretreatment HIV-1 resistance to INSTIs was low in the study sites, which supports the use of INSTIs in Cameroon. Nevertheless, further studies are necessary to assess the impact of polymorphic accessory INSTI DRMs on INSTI-based ART regimens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Wenk BM, Mbunkah HA, Nsanwe NN, et al. Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon. J Antimicrob Chemother. 2021. PMID: 32954411. doi:10.1093/jac/dkaa383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。